Showing results (1-10 of 893) with videos related to
Sort By:
Pageof 90
Future Oncology (London, England)|July 9, 2026
Enzalutamide in biochemically recurrent prostate cancer: clinical implications from EMBARK for real-world practiceStephen J Freedland, Neal D ShoreUrology|July 4, 2012
Treatment patterns in patients with prostate cancer and bone metastasis among US community-based urology group practicesStephen J Freedland, Akshara Richhariya, Huei Wang, et al.Prostate Cancer and Prostatic Diseases|September 7, 2023
Biochemical recurrence in patients with prostate cancer after primary definitive therapy: treatment based on risk stratificationNeal D Shore, Judd W Moul, Kenneth J Pienta, et al.Prostate Cancer and Prostatic Diseases|September 7, 2023
Application of next-generation imaging in biochemically recurrent prostate cancerJudd W Moul, Neal D Shore, Kenneth J Pienta, et al.BMJ Open|August 13, 2021
A phase 3 randomised study of enzalutamide plus leuprolide and enzalutamide monotherapy in high-risk non-metastatic hormone-sensitive prostate cancer with rising PSA after local therapy: EMBARK study designStephen J Freedland, Ugo De Giorgi, Martin Gleave, et al.Reviews in Urology|November 26, 2020
Current and Future Management of Locally Advanced and Metastatic Prostate CancerNeal D ShoreImmunotherapy|August 17, 2011
Phacilitate Barcelona active immunotherapeutics forum. 11-13 May 2011, Barcelona, SpainNeal D ShoreImmunotherapy|April 26, 2014
PROSTVAC® targeted immunotherapy candidate for prostate cancerNeal D ShoreUrology|February 16, 2015
Radium-223 dichloride for metastatic castration-resistant prostate cancer: the urologist's perspectiveNeal D ShorePageof 90